Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA decisions on Bydureon, Nulojix, Avastin, Pradaxa, Simponi and others

This article was originally published in Scrip

Executive Summary

The 15 April update from the European Medicines Agency advisory group, the Committee for Medicinal Products for Human Use, brought forth a number of important decisions, including approval recommendations for Lilly's Bydureon and BMS's Nulojix, and a reversal of last December's opinion not to recommend Roche's Avastin as a first line treatment for metastatic breast cancer.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts